N-Light™ rapid tests are driven by the ultra-sensitive AquaSpark™ platform technology and pioneering phage science.
NEMIS is proud to introduce AquaSpark™, an innovative platform technology that revolutionises the detection of live bacteria through chemiluminescence. This technology is based on synthetic molecules specifically designed to emit light when interacting with bacterial enzymes. Our exclusive global rights, secured through a licensing agreement with Ramot at Tel Aviv University, encompass three pending patents that distinguish us in the field of microbiology.
The chemiluminescent light generated by AquaSpark™ is 1000 times brighter than conventional molecules. As a result, our N-Light™ solution represents a cutting-edge technology for highly sensitive detection across a broad range of applications. Thanks to the virtually limitless potential of the AquaSpark™ modular toolbox, the N-Light™ platform can be customised to detect any selected microorganism, including bacteria, parasites, viruses, or fungi.
NEMIS has developed unique bacteria-specific enrichment broths containing carefully designed bacteriophage cocktails to selectively eliminate competing microflora. NEMIS has assessed and utilises 16 individual phages to suppress competing microflora and false-positive bacteria, ensuring precise detection of target bacteria without interference. This makes our tests more accurate and specific than competitors’ rapid tests. In other words, this distinctive enrichment broth enhances the growth of targeted pathogens in a single enrichment step. As a result, NEMIS has achieved increased specificity and sensitivity in N-Light™ rapid tests.
In addition to utilising phages for selectivity, NEMIS, in collaboration with ETH, has developed an innovative genetically modified reporter phage designed to function with AquaSpark™ for rapid and precise pathogen detection.
NEMIS has developed specialised formulations of small assay tablets (3 mm in diameter) that effectively shield AquaSpark™ from environmental factors, significantly extending the shelf life of the tests. These N-Light™ tablets also contain precise amounts of lysis agents where required and disintegrate in under 10 seconds — compared to over 10 minutes for conventional tablets — offering a superior user experience and improving assay efficiency.
AquaSpark™ lyophilisates and tablets undergo a rigorous quality control (QC) testing process at NEMIS. This encompasses physical property assessments and verification of the uniform distribution of active ingredients within each batch. We employ advanced technologies, such as ultra-high-performance liquid chromatography (UHPLC), to precisely detect the minute quantities of AquaSpark™ and other active ingredients in individual tablets (less than 0.05 milligrams).
We run a state-of-the-art biosafety laboratory for R&D in Au, Switzerland, where we specialise in rapidly developing robust assay formats.
Our ongoing field studies and pilot trials with clients enable us to refine our offerings and deliver bespoke solutions, particularly in food safety environments.
Explore our field studiesOur expertise in microbial food safety is unparalleled, allowing us to promptly address and resolve customer enquiries. This responsiveness not only strengthens our brand but also enhances customer satisfaction and loyalty, reinforcing NEMIS’s position as a leader in the microbial detection industry.